Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Response to ASX Price Query 3 pages 372.5KB
Regulatory Filings Classification · 91% confidence The document is a formal response letter from Prescient Therapeutics to the ASX’s price and volume query under Listing Rule 18.7. It is correspondence regarding regulatory compliance and continuous disclosure, not an annual or interim report, earnings release, investor presentation, or other specific category. It does not contain financial statements or new material information for investors, but is a regulatory filing to satisfy ASX rules. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-14 English
March 2026 Quarterly Update and Appendix 4C 8 pages 758.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'March 2026 Activities Report and Appendix 4C' and includes detailed quarterly financial data such as cash flow statements, cash reserves, and payments. It references the quarter ended 31 March 2026 and provides substantive financial data and analysis for that period. The Appendix 4C is a recognized quarterly cash flow report under ASX Listing Rule 4.7B, which is a standard interim/quarterly report format for Australian listed companies. The document also includes operational highlights and clinical program updates, typical of an interim report. It is not merely an announcement of a report but contains actual financial statements and analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
Investor Presentation 31 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Briefing' and contains detailed information about Prescient Therapeutics' business focus, technology, clinical trial data, market opportunity, and strategy. It includes extensive data on clinical trial phases, patient cohorts, safety profiles, and market forecasts. The content is forward-looking and strategic, aimed at investors, with no actual financial statements or regulatory filings included. It is a presentation-style document designed to inform investors about the company's progress and prospects rather than a formal financial report or regulatory filing. Therefore, it fits the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-04-29 English
Updated Securities Trading Policy 9 pages 343.8KB
Governance Information Classification · 95% confidence The document is titled 'Securities Trading Policy' and contains detailed rules and procedures regarding insider trading, trading restrictions, approval processes for trading company securities, and definitions related to securities and insider information. It is a policy document outlining internal rules for directors, officers, and employees about trading company shares and compliance with legal requirements. There is no financial data, earnings information, or report of financial performance. It is not an announcement or regulatory filing about a financial report or event. The content fits best under Governance Information, as it details the company's internal governance practices related to securities trading and compliance with insider trading laws.
2026-02-24 English
Appendix 4D and Half Year Financial Report 20 pages 1.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Appendix 4D Half-year report' and references the half-year ended 31 December 2025. It contains detailed financial statements including profit or loss, financial position, directors' report, auditor's review report, and notes to the financial statements. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The presence of an auditor's review report and detailed financial statements confirms this is a substantive financial report, not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2026
2026-02-23 English
December 2025 Quarterly Update and Appendix 4C 9 pages 282.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'December 2025 Activities Report and Appendix 4C' and includes detailed quarterly financial data such as cash flow statements, operating cash outflows, and cash balances. It also contains operational highlights, clinical program updates, and regulatory progress. The presence of the Appendix 4C cash flow report, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly financial and operational report. The document is comprehensive and contains substantive financial data and analysis for the quarter ended 31 December 2025, not merely an announcement or a brief summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2025
2026-01-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.